Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Hecolin and Hepatitis B Vaccine Co-administration
NCT02584543Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of HEV 239 in hepatitis E (HEV), sponsored by Xiamen Innovax Biotech Co., Ltd.. Started Oct 2015; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT02584543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584543.